Realm Therapeutics PLC Block Listing Application (8780T)

TIDMRLM

RNS Number : 8780T

Realm Therapeutics PLC

18 October 2017

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

Block Listing Application

18 October 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces that an application has been made for the block admission, in aggregate, of 21,139,826 ordinary shares of 10p each in the Company (the "Block Admission Shares") in relation to certain outstanding, but not yet exercised warrants. The Block Admission Shares will be available to be issued as needed to satisfy the valid exercise of the following warrants:

- 20,898,448 Block Admission Shares in relation to a portion of the warrants issued in connection with the recent placing to raise GBP19.3 million ($26 million), as approved by shareholders on 9 October 2017 (the "Placing"); and

- 241,378 Block Admission Shares in relation to a portion of the warrants issued in December 2013 (and adjusted as a result of the Placing) in conjunction with the establishment of a credit facility with the Company's bank, the remainder of which are already subject to an existing block listing.

This block admission is further to the Company's existing block listing of ordinary shares of 10p each in connection with the Company's equity plans and in respect of the warrants issued in connection with the credit facility.

It is expected that the block admission will become effective on 23 October 2017. When issued, the Block Admission Shares will be credited as fully paid and will rank pari passu with the existing ordinary shares of the Company.

Enquiries:

 
                                         [phone] 
 Realm Therapeutics plc                   1000 
 Alex Martin, Chief Executive Officer 
 Marella Thorell, Chief Financial 
  Officer and Chief Operating Officer 
 
                                         [phone] 
 FTI Consulting                           1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser           [phone] 
  and Broker)                             3000 
 Aubrey Powell / Lauren Kettle 
 

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSFFMFWWFWSEDS

(END) Dow Jones Newswires

October 18, 2017 02:00 ET (06:00 GMT)